Phase I study of tricyclic nucleoside phosphate.
A phase I study of tricyclic nucleoside phosphate was conducted in 20 adults with advanced cancer. Tricyclic nucleoside phosphate was given as an iv infusion over 15 minutes once every 3 weeks; the doses ranged from 25 to 350 mg/m2. Beginning at a dose of 250 mg/m2, hyperglycemia and elevation of hepatocellular enzymes were observed; at a dose of 350 mg/m2, two patients developed irreversible liver damage. Patients at all dose levels experienced reduction in serum phosphorus; reduction of serum calcium was noted only with the two highest doses. Nausea and vomiting occurred occasionally. Myelosuppression was not a prominent toxic effect. No major therapeutic responses were noted. Further clinical trials employing this schedule are probably not warranted.
D000073:Acenaphthenes; D000328:Adult; D000368:Aged; D001786:Blood Glucose; D001853:Bone Marrow / Q000187:drug effects; D002118:Calcium / Q000097:blood; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D008099:Liver / Q000201:enzymology; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009369:Neoplasms / Q000188:drug therapy*; D010758:Phosphorus / Q000097:blood; D012265:Ribonucleotides / Q000009:adverse effects / Q000627:therapeutic use*
D000073:Acenaphthenes; D001786:Blood Glucose; D012265:Ribonucleotides; D010758:Phosphorus; C014205:triciribine phosphate; D002118:Calcium